STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastatic Breast Cancer|HER2-positive Breast Cancer
Interventions: OTHER: Cessation of anti-HER2 treatment
Sponsor: Dana-Farber Cancer Institute
Collaborators: National Cancer Institute (NCI)|Gateway for Cancer Research|Susan G. Komen Breast Cancer Foundation|Translational Breast Cancer Research Consortium|Johns Hopkins University